TP53 and acute myeloid leukemia: The mutations and CNVs of m6A regulatory genes were associated with poorer cytogenetic risk and other clinic‐pathological or molecular features in AML.85 In addition, impaired m6A regulatory genes were notably associated with the presence of TP53 mutations in AML patients and both might play a complementary role in the maintenance of AML.85 Collectively, it is unknown whether single alteration or multiple changes in m6A modification profoundly affect leukaemia.